B-Lymphocyte transformed by EBV from 23 yr old female
Cell Type:
B cell
Tissue Origin:
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SF EH-100 4e5 56% 53% Plasmid (general) 400 ng 20 µl 96-well
SF FF-113 4e5 52% 50% Plasmid (general) 400 ng 20 µl 96-well
SF DN-100 4e5 45% 64% Plasmid (general) 400 ng 20 µl 96-well